Movement Alert｜Tempus AI Intraday Rise 5.09% in Regular Trading, Alzheimer’s drug research collaboration lifts sentiment

Market Focus10-24

On October 24, Tempus AI rose 5.09% in Regular Trading, trading near $67.14 per share, with turnover of $158 million.

The move followed the company’s announcement of a multi-year strategic collaboration with Bristol Myers Squibb and Pathos AI to use artificial intelligence and patient data to advance drug development for Alzheimer’s disease and other neurological conditions.

Under a five-year, $55 million agreement, Tempus AI will build a de-identified dataset covering hundreds of thousands of neurological patients for Pathos AI to license and analyze through its Foundry AI platform, supporting research into disease biology, disease progression, and clinical-trial design. Bristol Myers Squibb is also leading Pathos AI’s Series E financing and will gain access to the platform across its R&D portfolio, with three-year exclusive rights in neuroscience development programs. The announcement points to further commercialization of Tempus AI’s healthcare data infrastructure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment